PRIMARY CEREBRAL LYMPHOMA: AN ARGUMENT FOR THE USE OF ADJUNCTIVE SYSTEMIC CHEMOTHERAPY

M. A. Rosenthal*, W. P. Sherldan, M. D. Green, K. Liew, R. M. Fox

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Eleven patients with primary cerebral lymphoma were treated at a single institution over a 5 year period. Patient characteristics were typical of this rare disease. One patient died prior to receiving treatment and of the remaining 10, all received cranial irradiation and in addition, five received systemic cyclophosphamide, adriamycin, vincristine and prednisolone (CHOP) chemotherapy. Of the six patients who are alive and disease‐free, five received the combined modality therapy. The median survival for those patients receiving cranial irradiation alone was 18 months and for the combined modalities was 25+ months. Combination systemic chemotherapy, in addition to cerebral irradiation, may convey a survival benefit in patients with primary cerebral lymphoma but this requires further investigation with multicentre, prospective randomized trials.

Original languageEnglish
Pages (from-to)30-32
Number of pages3
JournalAustralian and New Zealand Journal of Surgery
Volume63
Issue number1
DOIs
StatePublished - Jan 1993
Externally publishedYes

Keywords

  • chemotherapy
  • primary cerebral lymphoma

Fingerprint

Dive into the research topics of 'PRIMARY CEREBRAL LYMPHOMA: AN ARGUMENT FOR THE USE OF ADJUNCTIVE SYSTEMIC CHEMOTHERAPY'. Together they form a unique fingerprint.

Cite this